23andMe (MEHCQ) Stock Price, News & Analysis

Company Overview

23andMe Holdings, Inc. (OTCMKTS: MEHCQ) is a personal genomics and biotechnology company that offers direct-to-consumer genetic testing services. Through an at-home saliva collection kit, consumers can access reports on ancestry composition, inherited traits, carrier status for certain genetic conditions, and predispositions to common health factors. The company combines proprietary laboratory processes with bioinformatics analysis to translate raw genetic data into personalized insights, delivering results via an online portal and mobile app.

Founded in 2006 and headquartered in Sunnyvale, California, 23andMe was co-founded by Anne Wojcicki, Linda Avey, and Paul Cusenza. Anne Wojcicki continues to serve as Chief Executive Officer, guiding the company’s expansion of both consumer services and research initiatives. In addition to its retail business, 23andMe has entered strategic collaborations with pharmaceutical and biotechnology partners to leverage its large, consented genetic database for drug discovery and development.

Serving millions of customers across North America, Europe, and parts of the Asia-Pacific region, 23andMe has established a global footprint in the genetic testing market. The company’s research arm focuses on aggregating de-identified genetic and phenotypic data to uncover novel insights into complex diseases. By balancing consumer-facing offerings with scientific partnerships, 23andMe aims to advance precision medicine and deepen understanding of human genetics.

Key Stats

• Today's Range: $3.50 to $3.50
• 50-Day Range: $3.50 to $3.50
• 52-Week Range: $0.47 to $6.21
• Volume: N/A
• Average Volume: 129,822 shs
• Market Capitalization: $96.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/22/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MEHCQ
• CIK: 1804591
• Web: www.23andme.com
• Phone: 650-938-6300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$280.89 million
• Net Margins: -130.25%
• Pretax Margin: -116.70%
• Return on Equity: -827.24%
• Return on Assets: -87.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $189.90 million
• Price / Sales: 0.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.97) per share
• Price / Book: -3.61

Miscellaneous

• Outstanding Shares: 27,541,000
• Free Float: 20,292,000
• Market Cap: $96.39 million
• Optionable: N/A
• Beta: 2.12